Access to high-priced medicines in lower-income countries in the WHO European Region
Oslo Medicines Initiative technical report
Monography
in English
| WHO IRIS
| ID: who-361751
Responsible library:
CH1.1
ABSTRACT
Lower-income countries (LICs) in the WHO European Region generally have poorer health status and more limited resources than higher-income countries. This creates pressing issues when making decisions on financing high-priced medicines. The market access strategies for innovative medicines in LICs usually follow the low-volume, high-price business model, which does not guarantee access for all potentially eligible patients. If the political will to make changes exists, however, several policy tools could be used that may improve patient access to these medicines. This technical report describes specific constraints of LICs related to public financing of high-priced medicines, and summarizes policy considerations to improve access to high-priced medicines in LICs in three areas, including price-control mechanisms, tools to increase the negotiation power of health-care payers and tools to facilitate appropriate prescribing.
Full text:
Available
Collection:
Databases of international organizations
Health context:
SDG3 - Target 3.8 Achieve universal access to health
/
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Financial Arrangements
/
Multisectoral Coordination
/
Goal 5: Medicines, vaccines and health technologies
/
Target 3.8 Achieve universal access to health
Database:
WHO IRIS
Main subject:
Poverty
/
Europe
/
Health Services Accessibility
/
Medicine
Country/Region as subject:
Europa
Language:
English
Year:
2022
Document type:
Monography